AI Terminal
ROQUEFORT THERAPEUTICS PLC
Director's Dealing • Nov 24, 2025
5061_dirs_2025-11-24_a4e2a256-e2b9-40c0-858b-8abd4253b503.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6299I
Roquefort Therapeutics PLC
24 November 2025
24 November 2025
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Director/PDMR Shareholding
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, advises that Dr Darrin Disley, Interim Managing Director, has purchased ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:
| Number of Ordinary Shares Acquired | Average Price Paid per Share | Total Consideration Paid | Number of Ordinary Shares Now Held | % of Company's Issued Capital |
| 5,000,000 | 1.70 pence | £85,000.00 | 7,024,196 | 4.46% |
-ENDS-
Enquiries:
| Roquefort Therapeutics plc | +44 (0)20 3918 8633 |
| Stephen West (Chairman) / Dr Darrin Disley (Interim MD) | |
| SP Angel Corporate Finance LLP (Joint Broker) David Hignell / Vadim Alexandre / Devik Mehta |
+44 (0) 20 3470 0470 |
| Shard Capital Partners LLP (Joint Broker) Damon Heath |
+44 (0)20 4530 6926 |
| Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper |
+44 (0)20 7466 5000 |
| Peak IR (Investor Relations) Seb Wykeham |
+33 (0)7 44 44 15 42 |
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is focused on completing the proposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, most recently announced by the Company on 18 November 2025.
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com
This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Darrin Disley | |
| 2 | Reason for the notification | ||
| a) | Position/status | Interim Managing Director | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15 |
|
| b) | Nature of the transaction | Purchase of 5,000,000 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 1.70 pence per share | 5,000,000 | ||
| d | Aggregated information - Aggregated volume - Price |
- 5,000,000 - 1. 70p |
|
| e) | Date of the transactions | 21 November 2025 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBRBDBDSDDGUX